Rodman & Renshaw Initiates Coverage of Myrexis with Market Outperform and PT of $6

Rodman & Renshaw initiated its coverage of Myrexis

with a Market Outperform rating and a price target of $6. On Tuesday, MYRX lost 0.57% of its value to finish the day at $3.46. Its shares rebounded in today's pre-market trading, rising 1.45% to stand around $3.51.